A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics of YZJ-1139 in Healthy Participants
Latest Information Update: 12 Feb 2025
At a glance
- Drugs YZJ-1139 (Primary)
- Indications Insomnia
- Focus Adverse reactions
- Sponsors Shanghai Haiyan Pharmaceutical Technology
Most Recent Events
- 08 Nov 2024 New trial record